Monday 18th January 2021 GatewayC have produced a list of cancer charity support lines for people who may be worried about their cancer diagnosis, or are concerned about how COVID-19 might affect their cancer treatment. Please download this PDF resource or find the...
15th January 2021 Missed our free GatewayC webinar on Diagnosing Ovarian Cancer? Watch our recording here. In this webinar, GatewayC met Professor Gordon Jayson, Professor of Medical Oncology at The Christie NHS Foundation Trust, who answered key questions from our...
Neutropenic sepsis is a potentially fatal complication of anticancer treatment (particularly chemotherapy). Helpful hint: NICE have produced a COVID-19 rapid guideline on the delivery of systemic anticancer treatments. If patients present with COVID-19 symptoms this...
Potential pitfall: In the early course of the disease, pancreatic cancer may not cause any signs or symptoms. However, sudden onset diabetes in groups of patients for whom this would be unexpected can be an early indicator. Helpful hint: NICE NG12 guidelines recommend...
Potential pitfall:
A negative bowel screening test should not be used to make decisions about referral in a symptomatic patient. Sensitivity levels have been set very differently for screening and symptomatic Faecal Immunochemical Tests (FIT).
Helpful hint:
The screening sensitivity threshold is 120ug/g in England (150ug/g in Wales and 80ug/g in Scotland). In symptomatic patients, the NICE DG30 guidance recommends that results should be reported using a threshold of 10 micrograms of haemoglobin per gram of faeces.
Cancer Keys are brought to you by GatewayC.
Download this Cancer Key here
Read the NICE NG12 guidance here
Access GatewayC’s Faecal Immunochemical Test (FIT) course here